The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
This transaction fundamentally strengthens Scinai's CDMO platform
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Subscribe To Our Newsletter & Stay Updated
